Spineology raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and its existing investor, RC Capital.
OptiMesh technology is reported to be the only in situ patient specific, expandable implant on the market. OptiMesh is delivered through the smallest insertion portal in the lumbar interbody market and conforms to a patient’s unique endplate morphology, expanding to one of the largest implant footprints available. A single implant may be used for multiple lumbar fusion approaches.
Brian Snider, Spineology Chief Executive Officer, said, “OptiMesh’s powerful distraction forces and conformance to the endplates provide strength and stability to restore disc height, achieve alignment goals, and promote robust fusion. It is evident that surgeons and patients desire less disruptive options to treat spinal disorders, further accelerating our opportunity.”
Spineology raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and its existing investor, RC Capital.
OptiMesh technology is reported to be the only in situ patient specific, expandable implant on the market. OptiMesh is delivered through the smallest insertion portal in the lumbar...
Spineology raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and its existing investor, RC Capital.
OptiMesh technology is reported to be the only in situ patient specific, expandable implant on the market. OptiMesh is delivered through the smallest insertion portal in the lumbar interbody market and conforms to a patient’s unique endplate morphology, expanding to one of the largest implant footprints available. A single implant may be used for multiple lumbar fusion approaches.
Brian Snider, Spineology Chief Executive Officer, said, “OptiMesh’s powerful distraction forces and conformance to the endplates provide strength and stability to restore disc height, achieve alignment goals, and promote robust fusion. It is evident that surgeons and patients desire less disruptive options to treat spinal disorders, further accelerating our opportunity.”
Copy to clipboard 
